News | June 01, 2021
Marksans Pharma Q4 FY21 profit up 86%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The facility is expected to be completed in 2024
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Subscribe To Our Newsletter & Stay Updated
